We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+19.41%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$16.6B
AUM Growth
+$2.17B
Cap. Flow
-$81M
Cap. Flow %
-0.49%
Top 10 Hldgs %
31.47%
Holding
166
New
39
Increased
28
Reduced
33
Closed
30

Top Buys

Rank Stock Value
1
ARMK icon
Aramark
ARMK
+$366M
2
XLNX
Xilinx Inc
XLNX
+$332M
3
RTX icon
RTX Corp
RTX
+$299M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$289M
5
AVGO icon
Broadcom
AVGO
+$243M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$498M
2
INFO
IHS Markit Ltd. Common Shares
INFO
+$299M
3
ABBV icon
AbbVie
ABBV
+$298M
4
PANW icon
Palo Alto Networks
PANW
+$217M
5
BMY icon
Bristol-Myers Squibb
BMY
+$215M

Sector Composition

Rank Sector Weight
1 Healthcare 38.5%
2 Technology 14.31%
3 Communication Services 13.23%
4 Financials 10.05%
5 Industrials 8.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BRMK
51
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$73.1M 0.44%
7,170,213
– –
KSU
52
DELISTED
Kansas City Southern
KSU
$72.3M 0.44%
354,400
-39,600
-10% -$7.44M
EFX icon
53
Equifax
EFX
$22.6B
$71.5M 0.43%
370,684
-25,800
-7% -$4.34M
KRTX
54
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$71.1M 0.43%
700,000
– –
KYNB
55
Kyntra Bio
KYNB
$30.4M
$70.5M 0.42%
76,000
+2,000
+3% +$2.1M
BCAB icon
56
BioAtla
BCAB
$5.3M
$66.9M 0.4%
+39,341
New +$65.8M
GBIO
57
DELISTED
Generation Bio
GBIO
$64.3M 0.39%
226,882
+14,819
+7% +$4.76M
ARNA
58
DELISTED
Arena Pharmaceuticals Inc
ARNA
$57.6M 0.35%
750,000
+120,114
+19% +$9M
PACB icon
59
Pacific Biosciences
PACB
$420M
$54.5M 0.33%
2,100,000
-1,963,770
-48% -$33.4M
CYTK icon
60
Cytokinetics
CYTK
$10.7B
$49.9M 0.3%
2,400,000
+250,000
+12% +$4.57M
PTGX icon
61
Protagonist Therapeutics
PTGX
$9.99B
$48.9M 0.29%
2,425,000
-325,000
-12% -$6.99M
ALNY icon
62
Alnylam Pharmaceuticals
ALNY
$31.6B
$45.5M 0.27%
350,000
-850,000
-71% -$113M
ZGNX
63
DELISTED
Zogenix, Inc.
ZGNX
$45M 0.27%
2,250,000
– –
CLGX
64
DELISTED
Corelogic, Inc.
CLGX
$44.4M 0.27%
574,028
+229,028
+66% +$17.1M
AGIO icon
65
Agios Pharmaceuticals
AGIO
$1.98B
$43.3M 0.26%
1,000,000
-83,429
-8% -$3.3M
IONS icon
66
Ionis Pharmaceuticals
IONS
$9.93B
$42.4M 0.26%
+750,000
New +$37.4M
ANNX icon
67
Annexon
ANNX
$961M
$39M 0.23%
1,557,261
-100,000
-6% -$2.57M
RDUS
68
DELISTED
Radius Health, Inc.
RDUS
$37.6M 0.23%
2,107,400
– –
TVRD
69
Tvardi Therapeutics
TVRD
$24.8M
$37.3M 0.22%
68,472
+5,972
+10% +$3.13M
LNTH icon
70
Lantheus
LNTH
$6.53B
$35.7M 0.22%
2,650,000
– –
ZYME icon
71
Zymeworks
ZYME
$2.05B
$35.4M 0.21%
750,000
-102,200
-12% -$4.75M
KRYS icon
72
Krystal Biotech
KRYS
$10.3B
$31.5M 0.19%
525,000
+50,000
+11% +$2.5M
NVAX icon
73
Novavax
NVAX
$1.47B
$30.7M 0.18%
+275,000
New +$29.2M
NUVB icon
74
Nuvation Bio
NUVB
$2.43B
$29.3M 0.18%
+2,500,000
New +$26M
FOLD
75
DELISTED
Amicus Therapeutics
FOLD
$28.9M 0.17%
+1,250,000
New +$25.6M
1 2
3
4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q4 2020 Portfolio in Review

As of Q4 2020, Thomas Steyer held 166 positions worth $16.6B, up 15% from $14.5B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Thomas Steyer's Q4 2020 filing shows 39 new, 28 increased, 33 reduced and 30 closed positions. Its largest new stake was Aramark: 15,268,169 shares worth $424M. The largest sale was Immunomedics Inc, an estimated $498M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 45% a quarter earlier, followed by Technology and Communication Services.

  • Thomas Steyer's largest Q4 2020 buy was Aramark: 15,268,169 shares worth $424M.
  • Thomas Steyer added most to Willis Towers Watson in Q4 2020, an estimated $188M increase.
  • Thomas Steyer's biggest Q4 2020 reduction was AbbVie, cutting an estimated $298M.
  • Thomas Steyer fully exited Immunomedics Inc in Q4 2020, selling an estimated $498M.
  • Thomas Steyer's ten largest holdings make up 31% of its $16.6B portfolio in Q4 2020.
  • Thomas Steyer opened 39 new positions and closed 30 in Q4 2020.
  • Thomas Steyer's portfolio value rose 15% quarter-over-quarter to $16.6B.

Based on Farallon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.